Presepsin as a predictor of septic shock and mortality in patients with urinary tract infection according to the Sepsis-3 definitions

The objective of this study was to investigate whether presepsin can serve as a useful biomarker for predicting septic shock and mortality rates in patients with urinary tract infections (UTI) as defined by the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). This single-center and prospective observational study was carried out between December 2019 and December 2022 and included 171 UTI patients divided into two groups: a non-septic shock group (n = 121) and a septic shock group (n = 50). The primary outcome of this study was the development of septic shock; the secondary outcome was 30-day hospital mortality. Receiver operating characteristic (ROC) curves and multivariate regression analyses were performed to investigate the predictive value of presepsin levels for septic shock and the Cox proportional hazards model was used to determine the risk factors for 30-day hospital mortality in UTI patients. Septic shock patients had significantly higher serum levels of presepsin when compared to the non-septic shock group (p < 0.001). In multivariate logistic regression analysis, presepsin demonstrated its independent role as a risk factor for septic shock (odds ratio (OR): 1.002; 95% confidence interval (CI): 1.001–1.002; p < 0.001). The multivariate Cox proportional hazards model indicated that presepsin represents a significant predictor of 30-day hospital mortality in septic shock patients (hazard ratio (HR): 1.0005; 95% CI: 1.0001–1.001; p < 0.05). The ROC curve for diagnosing septic shock had an area under the curve (AUC) of 0.739 with a cutoff value of 447 pg/mL for presepsin. For the prediction of 30-day hospital mortality in patients with UTI, an optimal presepsin cutoff of 709 pg/mL was determined; ROC curve analysis yielded an AUC of 0.744. When applying the Sepsis-3 criteria, presepsin levels represented a significant independent risk factor for septic shock and 30-day hospital mortality in UTI patients.

Presepsin; Septic shock; Urinary tract infection; Emergency department

[1] Sekine Y, Kotani K, Oka D, Nakayama H, Miyazawa Y, Syuto T, et al. Presepsin as a predictor of septic shock in patients with urinary tract infection. BMC Urology. 2021; 21: 144.

[2] Zhang L, Zhang F, Xu F, Wang Z, Ren Y, Han D, et al. Construction and evaluation of a sepsis risk prediction model for urinary tract infection. Frontiers in Medicine. 2021; 8: 671184.

[3] Contenti J, Occelli C, Lemoel F, Ferrari P, Levraut J. Presepsin versus other biomarkers to predict sepsis and septic shock in patients with infection defined by Sepsis-3 criteria: the PREDI study of diagnostic accuracy. Emergencias. 2019; 31: 311–317.

[4] Vincent J, Bakker J. Blood lactate levels in sepsis: in 8 questions. Current Opinion in Critical Care. 2021; 27: 298–302.

[5] Weinberger J, Klompas M, Rhee C. What is the utility of measuring lactate levels in patients with sepsis and septic shock? Seminars in Respiratory and Critical Care Medicine. 2021; 42: 650–661.

[6] Claessens Y, Trabattoni E, Grabar S, Quinquis L, Der Sahakian G, Anselmo M, et al. Plasmatic presepsin (sCD14-ST) concentrations in acute pyelonephritis in adult patients. Clinica Chimica Acta. 2017; 464: 182–188.

[7] Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. Journal of Intensive Care. 2019; 7: 22.

[8] Piccioni A, Santoro MC, de Cunzo T, Tullo G, Cicchinelli S, Saviano A, et al. Presepsin as early marker of sepsis in emergency department: a narrative review. Medicina. 2021; 57: 770.

[9] Yamamoto T, Nishimura T, Kaga S, Uchida K, Tachibana Y, Esaki M, et al. Diagnostic accuracy of presepsin for sepsis by the new Sepsis-3 definitions. The American Journal of Emergency Medicine. 2019; 37: 1936–1941.

[10] Kahveci U, Ozkan S, Melekoglu A, Usul E, Ozturk G, Cetin E, et al. The role of plasma presepsin levels in determining the incidence of septic shock and mortality in patients with sepsis. Journal of Infection in Developing Countries. 2021; 15: 123–130.

[11] Kweon OJ, Choi J, Park SK, Park AJ. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. Journal of Critical Care. 2014; 29: 965–970.

[12] Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine. 2001; 29: 1303–1310.

[13] Levy MM, Artigas A, Phillips GS, Rhodes A, Beale R, Osborn T, et al. Outcomes of the surviving sepsis campaign in intensive care units in the USA and Europe: a prospective cohort study. The Lancet Infectious Diseases. 2012; 12: 919–924.

[14] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315: 801–810.

[15] Kaur R, Kaur R. Symptoms, risk factors, diagnosis and treatment of urinary tract infections. Postgraduate Medical Journal. 2021; 97: 803–812.

[16] Yang SS, Tsai J, Kanematsu A, Han C. Asian guidelines for urinary tract infection in children. Journal of Infection and Chemotherapy. 2021; 27: 1543–1554.

[17] Guliciuc M, Maier AC, Maier IM, Kraft A, Cucuruzac RR, Marinescu M, et al. The urosepsis—a literature review. Medicina. 2021; 57: 872.

[18] Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Medicine. 2000; 26: S064–S074.

[19] Bisarya R, Song X, Salle J, Liu M, Patel A, Simpson SQ. Antibiotic timing and progression to septic shock among patients in the ED with suspected infection. Chest. 2022; 161: 112–120.

[20] Gander RM, Byrd L, DeCrescenzo M, Hirany S, Bowen M, Baughman J. Impact of blood cultures drawn by phlebotomy on contamination rates and health care costs in a hospital emergency department. Journal of Clinical Microbiology. 2009; 47: 1021–1024.

[21] Velissaris D, Zareifopoulos N, Karamouzos V, Karanikolas E, Pierrakos C, Koniari I, et al. presepsin as a diagnostic and prognostic biomarker in sepsis. Cureus. 2021; 13: e15019.

[22] Lelubre C, Anselin S, Zouaoui Boudjeltia K, Biston P, Piagnerelli M. Interpretation of c-reactive protein concentrations in critically ill patients. BioMed Research International. 2013; 2013: 1–11.

[23] Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiological Research. 2000; 49: S57–S61.

[24] Singh K, Singh S, Kumar P, Khera D, Sharma P, Toteja N, et al. Is there a role of presepsin as a novel biomarker in pediatric sepsis? Indian Journal of Critical Care Medicine. 2022; 26: 712–716.

[25] Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Critical Care. 2013; 17: R168.

[26] Pizzolato E, Ulla M, Galluzzo C, Lucchiari M, Manetta T, Lupia E, et al. Role of presepsin for the evaluation of sepsis in the emergency department. Clinical Chemistry and Laboratory Medicine. 2014; 52: 1395–1400.

[27] Baik SM, Park J, Kim TY, Choi SH, Hong KS. Validation of presepsin measurement for mortality prediction of sepsis: a preliminary study. Acute and Critical Care. 2022; 37: 527–532.

[28] Arakawa K, Saeki A, Ide R, Matsushita Y. Presepsin cut-off value for diagnosis of sepsis in patients with renal dysfunction. PLOS ONE. 2022; 17: e0273930.

[29] Tsuchida T, Ie K, Okuse C, Hirose M, Nishisako H, Torikai K, et al. Determining the factors affecting serum presepsin level and its diagnostic utility: a cross-sectional study. Journal of Infection and Chemotherapy. 2021; 27: 585–591.